Eyenovia/$EYEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Eyenovia
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.
Ticker
$EYEN
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
14
ISIN
US30234E2037
Website
Eyenovia Metrics
BasicAdvanced
$56M
-
-$34.33
0.76
-
Price and volume
Market cap
$56M
Beta
0.76
52-week high
$12.37
52-week low
$0.85
Average daily volume
8.7M
Financial strength
Current ratio
0.342
Quick ratio
0.279
Long term debt to equity
-6.153
Total debt to equity
-114.747
Interest coverage (TTM)
-12.69%
Profitability
EBITDA (TTM)
-29.131
Gross margin (TTM)
-9,724.86%
Net profit margin (TTM)
-63,194.11%
Operating margin (TTM)
-45,147.84%
Management effectiveness
Return on assets (TTM)
-117.74%
Return on equity (TTM)
1,073.42%
Valuation
Price to revenue (TTM)
200.295
Price to book
-3.17
Price to tangible book (TTM)
-3.17
Price to free cash flow (TTM)
-0.543
Free cash flow yield (TTM)
-184.03%
Free cash flow per share (TTM)
-2,002.25%
Growth
Revenue change (TTM)
663.82%
Earnings per share change (TTM)
-42.69%
3-year revenue growth (CAGR)
-82.25%
3-year earnings per share growth (CAGR)
-7.53%
Eyenovia News
AllArticlesVideos
Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group
GlobeNewsWire·2 weeks ago
Eyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve Strategy
GlobeNewsWire·2 weeks ago
Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Eyenovia stock?
Eyenovia (EYEN) has a market cap of $56M as of July 01, 2025.
What is the P/E ratio for Eyenovia stock?
The price to earnings (P/E) ratio for Eyenovia (EYEN) stock is 0 as of July 01, 2025.
Does Eyenovia stock pay dividends?
No, Eyenovia (EYEN) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next Eyenovia dividend payment date?
Eyenovia (EYEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Eyenovia?
Eyenovia (EYEN) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.